Heaptalk, Jakarta — SwipeRx, Southeast Asia’s leading pharmacy platform, has secured its latest funds worth US$27 million in a Series B funding round in the form of equity and debt. The company intends to deliver its newest injection to enlarge pharmacy and logistic networking for B2B e-commerce and accelerate its technology innovation in Southeast Asia.
MDI Ventures is known to lead this funding round followed by multiple global investors including Bill and Melinda Gates Foundation, Johnson and Johnson Impact Ventures, and Susquehanna International Group (SIG).
This Singapore-based company recently has renewed its brand identity from mClinica Pharmacy Solutions into SwipeRx, a primary enterprise application. Perceiving from its business trajectory, this pharmacy platform has successfully recruited over 235,000 professional pharmacists and partnered with 45,000 drugstores in Southeast Asia to provide an excellent digital solution.
“We recognize the tremendous potential of SwipeRx. The platform is considered to resolve the pharmacy industry obstacles in Indonesia by linking multiple entrepreneurs into one platform. The pharmacy enterprise can utilize SwipeRx’s special features, including a retail purchasing system, national-scale logistic capacity, business financing options, and an integrated B2B platform. MDI Ventures is pleased to be a part of this platform growth journey throughout Indonesia and Southeast Asia,” Affirmed CEO of MDI Ventures, Donald Wihardja.
The SwipeRx platform plans to increase its pharmacy network to be a member, expand its logistic health service in fulfilling B2B market demands, accelerate technology innovation and seek new talents throughout Southeast Asia. With its strategic business plans, the company expects to increase pharmacy management capacity to present the most satisfactory service for patients.
The Founder and CEO of SwipeRx, Farouk Meralli, conveyed his statement regarding this investment, “Our expansion is swiftly realized our objective of establishing the most excellent pharmacy network in Southeast Asia in recent years. This fresh capital reinforces our commitment to supporting this highly segmented pharmaceutical sector to improve public health services.
Meralli further uttered that the company is pleased to lead the Southeast Asia market as a platform that supports the digital transformation of the pharmaceutical industry. He also expects to make SwipeRx become a one-stop platform to tackle several requisites, from education and procurement to inventory financing.
The company noticed a perfect opportunity to expand its community and increase the supply of medicines for pharmacies in Southeast Asia. With its strong team, namely over 400 people, this pharmacy company believes in enhancing its business reach across Southeast Asia. (SFM)
